Rebif® (interferon beta 1-a)
- Parent companies: EMD Serono, Inc. and Pfizer Inc.
- Administered through subcutaneous injections three times weekly.
- Approved for relapsing types of MS.
- May affect the immune system by decreasing damaging cells and increasing cells that suppress inflammation.
- One-year data from an ongoing two-year study show that the new formulation of Rebif is better tolerated than the original formulation; compared to an earlier trial (EVIDENCE study), percentage of those positive for neutralizing antibodies (NAbs) at 48 weeks was reduced; also, injection-site reactions were reduced by nearly two-thirds.
- Studied in combination with atorvastatin (Lipitor®); study found combination resulted in an increase in MRI and clinical disease activity; statins now believed to block the therapeutic effects of interferons, statins not recommended when taking an interferon.
- Studies being conducted with Rebif's effect on CIS.
- Data being analyzed for study comparing Rebif to Copaxone.